- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:protocol:olmesartan:kidney_disease [10.25.2018] – [Benefits of angiotensin receptor blockers] sallieq | home:protocol:olmesartan:kidney_disease [02.10.2019] – [Notes and comments] sallieq | ||
|---|---|---|---|
| Line 55: | Line 55: | ||
| MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. | MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. | ||
| - | The benefits of olmesartan on patients with kidney inflammation include: | + | The benefits of olmesartan on patients with kidney inflammation include |
| * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed> | * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed> | ||
| Line 95: | Line 95: | ||
| {{tag> | {{tag> | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| + | |||
| + | Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate < | ||
home/protocol/olmesartan/kidney_disease.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.